Navigation Links
Lead Trial Attorney in Clark County Hepatitis C Trial, Robert Eglet, Asks Jury to Award $10 Million Compensatory Damages for Anne Arnold, $2.5 Million for James Arnold
Date:10/6/2011

LAS VEGAS, Oct. 6, 2011 /PRNewswire/ -- This is being released by SCM:

(Photo:  http://photos.prnewswire.com/prnh/20111006/LA81891)

After 7 weeks of testimony and 4 hours of closing statements, lead trial attorney for the plaintiffs in the hepatitis C trial in Clark County Nevada, Robert Eglet, asked jurors to bring a verdict of $10 million in compensatory damages for Anne Arnold, $2.5 million in compensatory damages for James Arnold and to consider whether the Arnolds should receive punitive damages. 

Attorney Robert Eglet told jurors, corporate greed dictated the actions of the drug company Teva Pharmaceuticals. "The primary concern should be the safety of the patient. A responsible drug company should design, package and market the drug to reduce human error. The drug companies knew there was a problem with the jumbo infusion 50mL vials of Propofol in these endoscopy centers," said Eglet.

Eglet told jurors that every 50mL vial of Propofol was sent to the endoscopy centers with a vent spike labeled for multi dosing.  "The temptation and opportunity is too great for misuse and the drug company knew this. They took no steps to prevent this. They did nothing and Teva expert witnesses Craig Lea and Rosalie Lowe in depositions agreed that health care providers using 50mL vials in an endoscopy center create more of a proclivity to multi dose," said Eglet.  

Attorney Robert Eglet told the jury that production of the sedative Propofol was stopped within 3 weeks of the unprecedented $500 million verdict in the Chanin trial in May 2010. Teva Vice President, Craig Lea admitted under examination by Eglet that Teva turned the lights out in their Propofol plant 21 days after last year's verdict. 

The jury is now in deliberation.

Plaintiff Anne Arnold was exposed to the virus hepatitis C when a contaminated jumbo 50mL infusion vial of the anesthesia medication Propofol was reused during a colonoscopy procedure at the Endoscopy Center of Southern Nevada on July 13, 2007. The lawsuit filed by Mainor Eglet alleges design defect, breach of implied warranty for a particular purpose, failure to properly warn by sending a Dear Health Care Professional letter and duty to monitor.


'/>"/>
SOURCE SCM
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... CHICAGO , March 27, 2017  A ... Educators (AADE) found that Medicare,s Competitive Bidding Program (CBP) ... diabetes testing supplies. The lack of choice forces beneficiaries ... can have dire health consequences. AADE,s ... reports by AADE and others pointing out the inherent ...
(Date:3/27/2017)... 2017 FinancialBuzz.com News Commentary  ... Based on New Frontier Data,s sales ... cannabis is legal will generate $655 million in taxes on retail ... specific taxes, such as Washington State,s 37% ... from state sales taxes that are applied on all retail sales. ...
(Date:3/27/2017)... , March 27, 2017 BioLineRx Ltd. ... immunology, announced today that AGI-134, an immunotherapy for the treatment ... Agalimmune Ltd., will be featured at the upcoming American ... Washington, DC to be held on April ... ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Thank you to all who attended Capio ... , This event was exclusive to providers and offered an opportunity to collaborate and ... at the Manchester Grand Hyatt where attendees gathered for a lively discussion on trends ...
(Date:3/28/2017)... , ... March 28, 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals ... Quinn. , “There were things that his parents and teachers had asked of him that ... that he was going to defy the Almighty Creator. There were some who would have ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep ... apnea treatment, with or without a referral. Sleep apnea is often left untreated because ... sleepiness, morning headaches and chronic snoring. , Dr. Braasch seeks to raise awareness ...
(Date:3/27/2017)... Claire, WI (PRWEB) , ... March 27, 2017 ... ... accepting new patients for custom smile makeovers without requiring a referral. ... including orthodontics, gum disease treatment, cosmetic dentistry and dental implants. Whether patients have ...
(Date:3/27/2017)... ... 2017 , ... Drs. Justin Kolnick, Kara Diamond, Randall Barton, Keith Hope and ... key role this treatment plays in protecting oral health, along with the benefits of ... who need a root canal in White Plains, NY or their second location in ...
Breaking Medicine News(10 mins):